soul trial oral semaglutide cardiovascular outcomes 2024 results nejm (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine 📌 Most viewed this week

Say someone with anorexia decides, I'm going to enhance my anorexia by taking this drug that's going to be a big problem, says Dr Yeo

Nyathi Y, Wilkinson BM, Pool MR (2013) Co-translational targeting and translocation of proteins to the endoplasmic reticulum

At Formation, every peptide protocol starts with a thorough evaluation to determine whether BPC-157 is appropriate for your specific goals and health profile

Hybye C, Biller BMK, Ferran JM, Gordon MB, Kelepouris N, Nedjatian N, et al

Melanotan II has limited long-term human safety data, and individual responses may vary

DecramerMRutten-van MlkenMDekhuijzenPTroostersTvan HerwaardenCPellegrinoRet al